Aeterna Zentaris (AEZS) is scheduled to report its fourth-quarter financial results on March 26, Tuesday, after the regular trading hours. The specialty biopharmaceutical company is expected to post a loss of 19 cents per share, on revenue of $0.25 million, up 40% compared to the same period last year.
It may be noted the company has a remarkable history of beating street estimates.
During the same quarter last year, the company had reported a net loss of 3 cents per share on revenues of $0.9 million.
The company, which specializes in developing endocrine treatments, has seen its stock gain 156% in the trailing 52 weeks. Since the beginning of this year, the stock has increased by 37%, as investors pin their hopes on its diagnostic test Macrilen.
Macrilen is an FDA-approved prescription oral solution to test for adult growth hormone deficiency (AGHD).
The test was out-licensed to Strongbridge Ireland Limited last year for commercialization in Canada and the US. Strongbridge launched it in July last year, and AEterna will get a royalty on the sales.
READ: WHAT IS NASH AND WHICH BIOTECH FIRMS ARE VYING FOR THE FIRST-MOVER STATUS
The test got approval from European authorities earlier this year, and the management is likely to provide more updates on this during the post-earnings conference call.
AEZS has a 12-month average price target of $5.50, suggesting a 34% upside from the last close. The stock has an average rating of Moderate Buy.
Earnings Calendar: Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!
Most Popular
QCOM Earnings: Qualcomm Q2 2024 revenue and profit beat Street view
Semiconductor company Qualcomm, Inc. (NASDAQ: QCOM) reported an increase in earnings and revenues for the second quarter of 2024. The numbers came in above analysts' estimates. At $9.39 billion, March-quarter
Key takeaways from Amazon’s Q1 2024 earnings report
Amazon.com Inc. (NASDAQ: AMZN) had an upbeat start to fiscal 2024, delivering strong growth across the business in the first three months of the year. While the cloud segment continues
Key takeaways from Pfizer’s (PFE) Q1 2024 earnings report
Shares of Pfizer Inc. (NYSE: PFE) gained over 5% on Wednesday following the company’s announcement of its first quarter 2024 earnings results. Although the top and bottom line numbers decreased
Comments